News
Recursion plans to report results from the phase 2 study of REC-994 in treating cerebral cavernous malformation (CCM) in the third quarter of 2024. CCMs are abnormal, tightly packed small blood ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback